MedDataX Logo

Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries

NCT ID: NCT03322332

Last Updated: 2017-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-23

Study Completion Date

2018-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate whether the expression and production of adipokines secreted by the epicardial adipose tissue correlate with the degree of coronary atherosclerosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to investigate whether the expression and production of four adipokines \[adiponectin, omenin-1, resistin and retinol binding protein-4 (RBP4)\] secreted by the epicardial adipose tissue correlate with the degree of coronary atherosclerosis. Specifically, this study aims to investigate whether the expression and production of these adipokines is different between two sites of the heart, that are perfused by coronary arteries with different degrees of stenosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Atherosclerosis Adipokines

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

adiponectin omentin-1 resistin RBP4 epicardial fat Coronary artery disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NonDM-0

Nondiabetics without significant stenoses (\> 50%) in the coronary arteries

No interventions assigned to this group

NonDM-L

Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)

No interventions assigned to this group

NonDM-R

Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA

No interventions assigned to this group

NonDM-LR

Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA

No interventions assigned to this group

DM-0

Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries

No interventions assigned to this group

DM-L

T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA

No interventions assigned to this group

DM-R

T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA

No interventions assigned to this group

DM-LR

T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\) Individuals undergoing cardiac surgery

Exclusion Criteria

* Age \< 18 years
* HbA1c \> 7.0%
* Any change of antidiabetic medication the previous 3 months before the surgery
* GFR \< 60 mL/min/1.73 m2
* Liver disease
* Cancer
* Non-treated hyperthyroidism or hypothyroidism
* Autoimmune disease
* Infection
* Any change in body weight at least 5% the previous 3 months before surgery
* Significant dehydration.
* Taking any of the following drugs the previous 3 months before surgery: hormones, antiobesity drugs
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Ioannina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Georgios A. Christou

Cardiologist, Postdoctoral researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eustratios Apostolakis, Professor

Role: STUDY_DIRECTOR

University Hospital, Ioannina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Ioannina

Ioannina, , Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eustratios Apostolakis, Professor

Role: CONTACT

Phone: 0030 2651099679

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Vasiliki Kyrouli

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

741

Identifier Type: -

Identifier Source: org_study_id